Systemic medical therapy of melanoma

What is it?

Molecularly targeted therapy with BRAF inhibitor and MEK inhibitor; Immunotherapy with anti-PD1 or anti-CTLA4 or treatment and/or combinations with other drugs.

When is this procedure indicated?

It is indicated in patients with metastatic melanoma and/or in patients who have a high risk of developing metastases after removal of the primary tumor.


How is it performed?

The target therapy is administered by means of tablets that the patient can easily take at home, while the immunotherapy is administered intravenously.

Are you interested in receiving the treatment?

Contact us and we will take care of you.